登录 | 注册    关注公众号  
微信公众号
搜索
 > 【CD55】

CD55信息

英文名称:Complement decay-accelerating factor
中文名称:补体衰变加速因子
靶点别称:DAF,Complement decay-accelerating factor,CD55,CD55 Molecule (Cromer Blood Group),CD55 Molecule, Decay Accelerating Factor For Complement (Cromer Blood Group),CD55 Antigen,CR,Decay Accelerating Factor For Complement (CD55, Cromer Blood Group System),Cromer Blood Group Antigen,CHAPLE,CROM,TC,CD55 Antigens
上市药物数量:0
临床药物数量:3
最高研发阶段:临床二期

CD55产品列表

产品库
物种
标签
属性
货号 物种 产品描述 蛋白结构 纯度 活性
CD5-H5225
Human
Human CD55 / DAF Protein, His Tag
ACRO质量管理体系
 
评论(1)
CD5-H5225|Human CD55 / DAF Protein, His Tag
  1. 166XXXXXXX1
  2. 1人赞
  3. 用于筛选h CD55的纳米抗体,产品质量很好,送货物流也很快,能很好的满足我的实验需求,以后有需要还会在你们公司购买。
  4. 2023-02-16
 

CD55 分子别名

CD55,DAF,CR,CROM,TC

CD55 分子背景

CD55 is also known as DAF or decay­accelerating factor, is a member of the RCA (regulators of complement activation) family characterized by four to 30 SCRs (short consensus repeats) in their plasma-exposed regions. CD55 /DAF is a 70 kDa membrane protein that regulates the complement system on the cell surface. It prevents the assembly of the C3bBb complex (the C3-convertase of the alternative pathway) or accelerates the disassembly of preformed convertase, thus blocking the formation of the membrane attack complex. This glycoprotein is broadly distributed among hematopoietic and non-hematopoietic cells. It is a determinant for the Cromer blood group system. CD55 is known to bind CD97 via the first SCR. It also binds physiologically­generated C3 convertases with its second and third SCRs. Binding results in an accelerated “decay”, or dissociation of active C3 convertases, thus blocking the development of C’ attack complexes on nonforeign cells. Finally, viruses and bacteria are also known to utilize multiple SCR sites for infection.

CD55 前沿进展

CD55临床药物信息

英文名称 研发代码 研发阶段 公司 适应症 临床试验
Gebasaxturev V-937; CVA-21 临床二期 Viralytics Ltd 头颈癌, 胃癌, 膀胱癌, 乳腺癌, 前列腺癌, 转移癌, 黑色素瘤 详情
Recombinant coxsackievirus B3 临床一期 武汉博威德生物技术有限公司 肿瘤 详情
PAT-SC1 SC-1; PAT-SC1; PAT-SC-1 临床二期 Oncomab Gmbh 胃癌 详情

消息提示

请输入您的联系方式,再点击提交!

确定